Abingworth is a long-established and leading international investment group dedicated to the life sciences sector. With a transatlantic presence, the firm invests across all stages of development, including venture, growth, and clinical co-development. Abingworth supports companies that are developing innovative therapeutics, medical devices, and diagnostics. Founded in 1973, Abingworth was acquired by Carlyle in 2022, further enhancing its capabilities and reach in the global life sciences market.
Serves as a key hub for European investment activities, fund management, and strategic operations for the life sciences focused firm, coordinating with US offices.
Located in a prominent central London business district, offering modern facilities designed for collaboration, client meetings, and strategic decision-making. The emphasis is on a professional and functional environment.
Characterized by a highly specialized, collaborative, and intellectually rigorous environment. The culture is driven by deep scientific and financial expertise, with a focus on thorough due diligence, innovation, and fostering long-term value in life science ventures.
The London headquarters is crucial for Abingworth's transatlantic strategy, providing direct access to European life science innovation, capital markets, regulatory bodies, and a rich talent pool. It anchors the firm's European presence.
Abingworth operates with a strong transatlantic focus, anchored by its key offices in London (UK), Boston (MA, USA), and Menlo Park (CA, USA). This strategic geographical distribution enables the firm to effectively source, evaluate, invest in, and manage life science companies across Europe and North America. Core functions supported globally include deal origination and due diligence, portfolio company development and support, fund management, and investor relations. Its integration with Carlyle has further amplified its global reach, resources, and network.
Princes Court, 7 Princes Street
London
N/A
United Kingdom
Address: One Marina Park Drive, Suite 1410, Boston, MA 02210, USA
Leverages proximity to world-class academic institutions (like Harvard, MIT), leading research hospitals, and a high concentration of biotech and pharmaceutical companies to identify and nurture innovative life science enterprises.
Address: 275 Middlefield Road, Suite 200, Menlo Park, CA 94025, USA
Provides direct access to a vibrant entrepreneurial ecosystem, renowned research institutions (like Stanford, UCSF), a significant pool of venture capital, and specialized talent on the West Coast, facilitating investment in cutting-edge life science companies.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Abingworth' leadership includes:
Abingworth has been backed by several prominent investors over the years, including:
No major publicly announced executive hires or departures directly at Abingworth have been identified in the last 12 months (May 2023 - May 2024). The leadership team appears stable following its integration with Carlyle. Any changes are typically part of Carlyle's broader talent management.
Discover the tools Abingworth uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Abingworth likely utilizes standard corporate email formats based on employee names. The most common patterns for investment firms include first initial followed by last name, or first name separated from last name by a period.
[first_initial][last_name]@abingworth.com (e.g., jdoe@abingworth.com) or [first_name].[last_name]@abingworth.com (e.g. jane.doe@abingworth.com)
Format
kvemster@abingworth.com
Example
85%
Success rate
Abingworth News / Roche • December 7, 2023
Roche announced its definitive merger agreement to acquire Carmot Therapeutics, Inc., a clinical-stage biotechnology company in Abingworth’s portfolio focused on metabolic diseases. The transaction includes a $2.7 billion upfront payment and up to $400 million in milestone payments, signifying a major successful exit for Abingworth and its co-investors....more
BioSpace / Abingworth News • November 14, 2023
Gamma Biosciences, a life sciences tool platform created by KKR, announced the successful completion of its acquisition of Astrea Bioseparations from Abingworth and other shareholders. Astrea Bioseparations is a leading provider of chromatography solutions. This represents a significant realization for Abingworth's funds....more
Carlyle Newsroom • April 1, 2022
Global investment firm Carlyle announced it has completed its acquisition of Abingworth, a leading transatlantic life sciences investment firm. This strategic acquisition significantly expands Carlyle’s global healthcare capabilities and establishes a specialized life sciences investment platform....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Abingworth, are just a search away.